2025 Coding and Payment Guide for Medicare Reimbursement: The following are the 2025 Medicare coding and national payment rates for Spinal Cord Stimulation (SCS) procedures performed in an ambulatory surgical center.

CPT*1	DESCRIPTION	MULTIPLE SURGERY DISCOUNTING ²	STATUS INDICATOR ³	NATIONAL AVERAGE PAYMENT ⁴
Lead & Pulse Generator Placement Codes				
63650	Percutaneous implantation of neurostimulator electrode array, epidural	N	J8	\$5,084
63655	Laminectomy for implantation of neurostimulator electrodes, plate/ paddle, epidural	N	J8	\$18,105
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver	N	18	\$26,282
Revision of Lead and Pulse Generators				
63663	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed	N	J8	\$5,159
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed	N	J8	\$9,132
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array	Υ	A2	\$1,944
Removal of Leads and Pulse Generator				
63661	Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed	N	G2	\$925
63662	Removal of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed	Υ	G2	\$1,944
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array	Υ	A2	\$1,944

³ASC Status Indicators – J8: Device-intensive procedure; paid at adjusted rate, G2: Non office-based surgical procedure added in CY 2008 or later, payment based on OPPS relative payment weight, A2: Surgical procedure on ASC list in CY 2007; payment based on OPPS relative weight, subject to multiple reduction rule.

Indications for Use. The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, Diabetic Peripheral Neuropathy of the lower extremities, intractable low back pain and leg pain, radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), aradhoxidits, multiple back surgeries. The Boston Scientific Spectra WaveWirter Alpha¹⁰¹ And WaveWirter Alpha¹⁰¹ Prime SCS Systems are also indicated as an aid in the management of chronic intractable unilateral or bilateral to but act and leg pain without prior back surgery. Contraindications, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical candidates, or are pregnant. Refer to the Instructions for Use provided with the SCS System or Pain.com for potential adverse effects, warnings, and precautions prior to using this product.

Warning: Stimulation modes. Only paresthesia-based stimulation mode has been evaluated for effectiveness in the diabetic peripheral neuropathy (DPN) population.

Disclaimer: Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific procurages providers to submit appropriate doalings for services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and complywith Medicare national coverage determinations (NCD). Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and erimbursement matters. Boston Scientific does not promote the use of its products outside therite FDA-approved label. Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. All trademarks are the property of their respective owners. The coding options isted within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options. This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for selecting the site of service and treatment modalities appropriate for the patient based on medically appropriate lender of machine the

- CPT Copyright 2024 American Medical Association. All rights reserved. CPT[®] is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. TheAMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein
- 2. In the case that multiple procedures are billed and coded, payment is typically made at 100% of the rate for the first procedure, and 50% of the rate for the second and all succeeding procedures. Such procedures subject to this discounting are marked "Y". However, procedure marked "N" are not subject to discounting, and are paid at 100% in full, regardless of whether they are submitted with other procedures.
- 3. ASC Status indicators:
 - J8:Device-intensive procedure: paid at adjusted rate.
 - G2:Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight.
 - A2:Surgical procedure on ASC list in CY 2007; payment based on OPPS relative weight, subject to multiple reduction rule
- 2025 Medicare National Average payment rates, unadjusted for wage. "National Average Payment" is the amount Medicare determines to be the maximum allowance for any Medicare covered procedure.
 - Actual payment will vary based on the maximum allowance less any applicable deductibles, co-insurance



25155 Rye Canyon Loop Valencia, CA 91355 www.bostonscientific.com

©2025 Boston Scientific Corporation or its affiliates. All rights reserved.

NM-45910-AW